Skip to main content
Glama

Guidetopharmacology

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly, idempotent, and non-destructive. The description adds valuable behavior beyond this: graceful degradation of LEI/FIGI enrichment, internal cascading through endpoints, the `figi_candidates`/`unresolved` output distinction, and the ISIN-to-LEI mapping path. This gives the agent a realistic model of what happens inside the call.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but its density is justified by the tool's complexity and breadth. It front-loads the core purpose, then provides structured detail per entity type. A few parenthetical asides could be trimmed, but overall every sentence contributes meaning; minor redundancy keeps it from a perfect score.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with two parameter types and no output schema, the description covers input semantics, return fields (CIK, ticker, LEI, FIGI, RxCUI, etc.), ownership data, fallback behavior, and edge cases like non-US issuers. An agent has everything needed to decide when and how to call it correctly, and can anticipate the kind of result it will get.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, yet the description still adds substantial field-level meaning. It enumerates accepted input forms for `value` (ticker, CIK, ISIN, name), gives a drug example, and provides a critical formatting rule about passing only the entity name, not the full noun phrase. This is exactly the kind of semantic guidance that prevents misinvocation.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb (resolve) and resource (user-spoken names to canonical identifiers), then lists concrete identifier types per entity type. It clearly distinguishes the tool's scope from others by framing it as the gateway for ID lookup tasks, and the example utterances make the purpose immediately recognizable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The explicit instruction 'Use FIRST whenever you have a name but need an ID' provides a direct usage policy. It also explains when the tool is not needed (when you already have an ID) and mentions that it replaces 2-3 manual lookups, giving the agent a clear decision rule.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Guidetopharmacology toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Many tools have overlapping purposes, such as multiple ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) that differ only subtly, and a large set of prediction market tools (bet_research, polymarket_arbitrage, polymarket_edges, etc.) that can be easily confused. Entity tools like entity_profile, recent_changes, and compare_entities also overlap significantly. An agent would struggle to pick the right tool without careful reading.

Naming Consistency2/5

Tool names mix snake_case (ask_pipeworx, deep_research, forget) and descriptive phrases without a consistent verb_noun pattern. Some start with verbs (compare, generate, scan) while others are nouns or compound phrases (pipeworx_trending, polymarket_fill_risk). This inconsistency makes it hard to predict tool names.

Tool Count2/5

With 35 tools, this MCP server is overly large and covers many diverse domains (data querying, prediction markets, pharmacology, npm scanning, brand visibility, etc.). Typically, a well-scoped server has 5-15 tools; 35 is excessive and suggests a lack of focus, making it unwieldy for an agent to manage.

Completeness2/5

Despite the large number of tools, the server has notable gaps. For example, the pharmacology section only offers search and interaction tools but no create/update/delete. The memory tools are limited to save/recall/forget. Many meta-tools (discover_tools, suggest_questions) exist but add little substance. The server covers many domains superficially rather than providing full lifecycle coverage for any one domain.

Resources